Maxim Weekly Maxim Weekly

PayPal filed to create PayPal Bank, a Utah industrial loan company, aiming to take FDIC-insured deposits, offer interest-bearing accounts, and potentially gain direct card-network membership. If approved, the structure could lower third-party costs, provide cheaper deposit funding, and improve lending margins as PayPal expands small-business credit. The upside is paired with meaningful uncertainty, since regulatory approval, capital requirements, and execution will determine whether the move translates into durable earnings impact.

UnitedHealth agreed to sell Banmedica to Patria for $1 billion, completing a multi-year exit from South America and freeing capital to refocus on U.S. priorities. Separately, a DOJ-backed settlement cleared the path for its $3.3 billion Amedisys deal, though divestitures and monitoring raise the bar for integration execution. Offsetting those positives, UnitedHealth paused its full-year 2025 outlook amid leadership changes, amplifying uncertainty as investors watch Medicare Advantage margins, Optum growth, and ongoing legal scrutiny including an opioid-related lawsuit against Optum.

Wells Fargo options activity skewed bullish, with call-heavy flow targeting a wide range of strikes over the next three months, a signal that some institutions are positioning for upside while accepting time-decay risk. On the fundamental side, Keefe, Bruyette & Woods raised its price target to $101 as the broader analyst picture remains a Moderate Buy, supported by a recent beat on EPS and revenue and improving profitability metrics. Strategically, Wells Fargo is renovating more than half of its branch network to drive engagement and cross-sell, with credit cards highlighted as a growth lever alongside efficiency initiatives like workforce reductions and AI.

Amgen's expanded UPLIZNA approval in generalized myasthenia gravis adds a commercial catalyst and strengthens its rare-disease and immunology footprint. Institutional activity was mixed, with one large fund reducing its stake while other buyers added, against a backdrop of Amgen beating earnings and revenue, lifting FY25 guidance, and raising its quarterly dividend to $2.52. The key debate is whether new product momentum and pipeline execution can offset biosimilar erosion, pricing pressure, and rising R&D and manufacturing costs.

American Express highlighted security as a key driver of Open Banking adoption, with survey results pointing to security as the top incentive for many UK shoppers to use bank-transfer-based payments. At the same time, CEO Steve Squeri warned that merchant surcharges on premium AmEx cards could be harmful for customers and potentially dampen spending, a risk tied to evolving rules after a Visa and Mastercard settlement. With credit metrics described as steady and an updated Morgan Stanley target, the near-term focus shifts to how merchant pricing, regulation, and consumer spending trends interact ahead of earnings.